Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Rethinking the Approach to Managing Postmenopausal Vulvovaginal Symptoms

Rethinking the Approach to Managing Postmenopausal Vulvovaginal Symptoms Research Original Investigation Efficacy of Vaginal Estradiol or Moisturizer vs Placebo for Postmenopausal Vulvovaginal Symptoms development and psychometric properties. capsule for symptomatic vulvar and vaginal 44. Palma F, Xholli A, Cagnacci A; Writing Group of Maturitas. 1996;24(3):161-175. atrophy. Menopause. 2017;24(4):409-416. the AGATA Study. Management of vaginal atrophy: a real mess. results from the AGATA Study. 31. Spitzer RL, Kroenke K, Williams JB, Löwe B. A 38. Bachmann GA, Komi JO; Ospemifene Study Gynecol Endocrinol. 2017;33(9):702-707. brief measure for assessing generalized anxiety Group. Ospemifene effectively treats vulvovaginal disorder: the GAD-7. Arch Intern Med. 2006;166 atrophy in postmenopausal women: results from a 45. Portman D, Shulman L, Yeaw J, et al. One-year (10):1092-1097. pivotal phase 3 study. Menopause. 2010;17(3): treatment persistence with local estrogen therapy 480-486. in postmenopausal women diagnosed as having 32. Gilbody S, Richards D, Brealey S, Hewitt C. vaginal atrophy. Menopause. 2015;22(11):1197-1203. Screening for depression in medical settings with 39. Labrie F, Archer DF, Koltun W, et al; VVA the Patient Health Questionnaire (PHQ): Prasterone Research Group. Efficacy of intravaginal 46. Weissmann-Brenner A, Bayevsky T, Yoles I. a diagnostic meta-analysis. J Gen Intern Med.2007; dehydroepiandrosterone (DHEA) on moderate to Compliance to vaginal treatment-tablets versus 22(11):1596-1602. severe dyspareunia and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Rethinking the Approach to Managing Postmenopausal Vulvovaginal Symptoms

JAMA Internal Medicine , Volume 178 (5) – May 19, 2018

Loading next page...
 
/lp/american-medical-association/rethinking-the-approach-to-managing-postmenopausal-vulvovaginal-iA8Sydg1cP
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2018.0094
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Efficacy of Vaginal Estradiol or Moisturizer vs Placebo for Postmenopausal Vulvovaginal Symptoms development and psychometric properties. capsule for symptomatic vulvar and vaginal 44. Palma F, Xholli A, Cagnacci A; Writing Group of Maturitas. 1996;24(3):161-175. atrophy. Menopause. 2017;24(4):409-416. the AGATA Study. Management of vaginal atrophy: a real mess. results from the AGATA Study. 31. Spitzer RL, Kroenke K, Williams JB, Löwe B. A 38. Bachmann GA, Komi JO; Ospemifene Study Gynecol Endocrinol. 2017;33(9):702-707. brief measure for assessing generalized anxiety Group. Ospemifene effectively treats vulvovaginal disorder: the GAD-7. Arch Intern Med. 2006;166 atrophy in postmenopausal women: results from a 45. Portman D, Shulman L, Yeaw J, et al. One-year (10):1092-1097. pivotal phase 3 study. Menopause. 2010;17(3): treatment persistence with local estrogen therapy 480-486. in postmenopausal women diagnosed as having 32. Gilbody S, Richards D, Brealey S, Hewitt C. vaginal atrophy. Menopause. 2015;22(11):1197-1203. Screening for depression in medical settings with 39. Labrie F, Archer DF, Koltun W, et al; VVA the Patient Health Questionnaire (PHQ): Prasterone Research Group. Efficacy of intravaginal 46. Weissmann-Brenner A, Bayevsky T, Yoles I. a diagnostic meta-analysis. J Gen Intern Med.2007; dehydroepiandrosterone (DHEA) on moderate to Compliance to vaginal treatment-tablets versus 22(11):1596-1602. severe dyspareunia and

Journal

JAMA Internal MedicineAmerican Medical Association

Published: May 19, 2018

References